Low-Dose Perioperative Corticosteroids Can Be Administered Without Additional Morbidity in Patients Undergoing Bilateral Total Knee Replacement: A Retrospective Follow-up Study of a Randomized Controlled Trial

Abstract

Background: Short-term benefits of perioperative corticosteroid injections (CSIs) for bilateral total knee replacement (BTKR) include suppressed inflammation, improved knee motion, and reduced pain. Very little is known about the long-term benefits, complications, and safety of corticosteroids administered in the perioperative period. Purpose: We sought to compare 3-year follow-up outcomes of BTKR patients who received perioperative CSI with those who received placebo. We hypothesized that there would be no statistically significant differences in functional outcomes or adverse events based on whether or not CSIs were administered in the perioperative period. Methods: We conducted a retrospective review of chart and registry data of BTKR patients from a prior randomized controlled trial to compare outcomes in patients who received hydrocortisone vs placebo injections after BTKR (ClinicalTrials.gov: NCT01399268 and NCT01815918). Outcomes were compared at 6 and 12 weeks and at 1, 2, and 3 years. The Knee Injury and Osteoarthritis Outcome Scores (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were used to evaluate clinical outcomes. Cochran-Mantel-Haenszel tests were used to compare the risk of complications between treatments after adjustment for trial. When possible, summary relative risk estimates were calculated using the Mantel-Haenszel method. Results: No BTKR patients in the treatment group developed an infection. The risk of complications did not increase in patients who received CSI compared with those who received placebo. Patients in the CSI group experienced greater reductions in pain and stiffness, though these results were not statistically significant. There were no statistically significant differences in the KOOS-Symptoms, KOOS-Activities of Daily Living, KOOS-Sports, KOOS-Quality of Life, or WOMAC Function scores. Conclusions: Low-dose corticosteroids can be administered in selected patients who undergo BTKR without increasing the risk of adverse events. At 3-year follow-up, administration of low-dose corticosteroids did not result in superior clinical outcomes scores when compared with placebo.

Keywords

corticosteroids inflammation mediators bilateral total knee arthroplasty postoperative complications perioperative care

Get full access to this article

View all access options for this article.

References

Bedard

Pugely

Elkins

, et al. The John N. Insall award: do intraarticular injections increase the risk of infection after TKA? Clin Orthop Relat Res. 2017;475:45–52.

Chai

Liu

You

Wang

Efficacy of additional corticosteroid in a multimodal cocktail for postoperative analgesia following total knee arthroplasty: a meta-analysis of randomized controlled trials. Pain Pract. 2019;19:316–327.

Christensen

Jacobs

Jennings

HR.

Effect of periarticular corticosteroid injections during total knee arthroplasty. A double-blind randomized trial. J Bone Joint Surg Am. 2009;91:2550–2555.

Jules-Elysée

. Steroids in bilateral total knee replacement. Available at: https://clinicaltrials.gov/ct2/show/NCT01399268. Accessed February 24, 2021

Jules-Elysée

. The effect of low dose corticosteroids on perioperative markers of thrombosis and fibrinolysis in total knee replacement. Available at: https://clinicaltrials.gov/ct2/show/NCT01815918. Accessed February 24, 2021.

Jules-Elysée

Lipnitsky

Patel

, et al. Use of low-dose steroids in decreasing cytokine release during bilateral total knee replacement. Reg Anesth Pain Med. 2011;36:36–40.

Jules-Elysée

Wilfred

Memtsoudis

, et al. Steroid modulation of cytokine release and desmosine levels in bilateral total knee replacement: a prospective, double-blind, randomized controlled trial. J Bone Joint Surg Am. 2012;94:2120–2127.

Klement

Luzzi

Siddiqi

Valichka

Sharkey

PF.

Intra-articular corticosteroid injection following total knee arthroplasty: is it effective?

J Arthroplasty. 2019;34:303–308.

Liu

Ahmet

Ward

, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.

10.

Lunn

Kehlet

Perioperative glucocorticoids in hip and knee surgery—benefit vs. harm? A review of randomized clinical trials. Acta Anaesthesiol Scand. 2013;57:823–834.

11.

McLawhorn

Beathe

YaDeau

, et al. Effects of steroids on thrombogenic markers in patients undergoing unilateral total knee arthroplasty: a prospective, double-blind, randomized controlled trial. J Orthop Res. 2015;33:412–416.

12.

Memtsoudis

Valle

Jules-Elysse

, et al. Perioperative inflammatory response in total knee arthroplasty patients: impact of limb preconditioning. Reg Anesth Pain Med. 2010;35:412–416.

13.

Mills

Elman

Foran

JRH

. The risk of acute infection following intra-articular corticosteroid injection into a pre-existing total knee arthroplasty. J Arthroplasty. 2018;33:216–219.

14.

Richardson

Schairer

Sculco

PK.

Comparison of infection risk with corticosteroid or hyaluronic acid injection prior to total knee arthroplasty. J Bone Joint Surg Am. 2019;101:112–118.

15.

Sadr

Walker

. The balancing act of the inflammatory cascade after bilateral total knee arthroplasty commentary on an article by Kethy M. Jules-Elysee, MD, et al.: “steroid modulation of cytokine release and desmosine levels in bilateral total knee replacement. A prospective, double-blind, randomized controlled trial.” J Bone Joint Surg Am. 2012;94:e1791–e1792.

16.

Tsukada

Wakui

Hoshino

The impact of including corticosteroid in a periarticular injection for pain control after total knee arthroplasty: a double-blind randomised controlled trial. Bone Joint J. 2016;98-B:194–200.